News
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The French company also has emphasized Beyfortus’ duration of protection through six months, which is now reflected on its new label in Europe.
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...
MarioGuti Most major stock indexes across the globe ended the week higher, as renewed optimism around US-China trade talks ...
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...
An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season: Paris Tuesday, June 10, 2025, 11:00 Hrs [IST] Sanofi is shipp ...
France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback